Therapeutic effects of a long-acting formulation of lanreotide in Korean patients with acromegaly

Yang, Sae Jeong; Seo, Young Jin; Eun, Chai Ryoung; Chung, Hye Soo; Choi, Hye Jung; Kim, Nam Hoon; Kim, Hye Sook; Park, Ju Ri; Kim, Dong Jin; Yoo, Hye Jin; Park, Soo Yeon; Lee, Yun Jeong; Ryu, Ohk Hyun; Kim, Hee Young; Lee, Kye Won; Seo, Ji A; Kim, Sin Gon; Choi, Dong Seop; Baik, Sei Hyun

Abstract

BACKGROUND: The present study was conducted to examine the effects of a long-acting formulation of lanreotide (Somatulin-Autogel(R)) in Korean acromegalic patients who had undergone surgery.
METHODS
The subjects in the study were 11 acromegalic patients (5 men and 6 women) who had undergone transsphenoidal tumor resection at Korea University Guro Hospital. The anthropometric parameters, blood pressure, fasting blood glucose (FBG), IGF-1, HbA1C, mass size and GH level following a 75 gm oral glucose tolerance test (OGTT) were measured in each subject before and after treatment with a long-acting formulation of lanreotide.
RESULTS
The median age of the subjects was 41 yrs (range: 28-52 yrs) (Table 1). The mean pre-operative levels of serum IGF-1 in the 11 patients was 1185+/-323.58 ng/mL, and post-operatively it was 862+/-314.06 ng/mL. The mean serum IGF-1 concentration decreased from 862+/-314.06 ng/mL to 549+/-371.62 ng/mL after 6 months treatment with the long-acting formulation of lanreotide (p=0.003, vs baseline, n=11), and it decreased further to 439+/-342.53 ng/mL after 12 months treatment (p=0.005 vs baseline, n=10) (Table 3). Two patients achieved the target level of IGF-1. The HbA1C measured before and after lanreotide treatment was 5.8+/-0.5% and 5.9+/-0.3%, respectively.
CONCLUSIONS
This study showed that a long-acting formulation of lanreotide decreased the IGF-1 and GH levels without significant side effects. In spite of the small number of subjects in this study, these findings suggest that this formulation of lanreotide is effective for the post-operative management of acromegaly.